Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.07.2022 | Case report

Brexucabtagene-autoleucel

Cytokine release syndrome and immune effector cell associated neurotoxicity syndrome: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Nie E, et al. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with CD19 CAR T-cell lymphoma therapy. Journal of Neuropathology and Experimental Neurology 81: 464, No. 6, Jun 2022. Available from: URL: http://doi.org/10.1093/jnen/nlac027 [abstract] Nie E, et al. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with CD19 CAR T-cell lymphoma therapy. Journal of Neuropathology and Experimental Neurology 81: 464, No. 6, Jun 2022. Available from: URL: http://​doi.​org/​10.​1093/​jnen/​nlac027 [abstract]
Metadaten
Titel
Brexucabtagene-autoleucel
Cytokine release syndrome and immune effector cell associated neurotoxicity syndrome: case report
Publikationsdatum
01.07.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-19132-7

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Prednisone

Case report

Metamfetamine

Case report

Covid-19-vaccine